NY-IWBI
5.2.2020 22:09:05 CET | Business Wire | Press release
The International WELL Building Institute (IWBI) announced today that it has passed the 500-million-square-foot mark of buildings registered and certified under the WELL Building Standard (WELL). The milestone quickly follows this month’s earlier announcement that the number of WELL Accredited Professionals (APs) and registrants has exceeded 10,000, further evidence of the accelerating growth of the global movement to help people thrive through better buildings and communities and stronger organizations.
“With more than 4,000 projects in nearly 60 countries and spanning all space types – offices, schools, hotels, residences and more – it’s clear that this second wave of sustainability has gathered powerful momentum,” said IWBI Chairman and CEO Rick Fedrizzi. “To reach a half-billion square feet of spaces applying WELL is to positively impact the health and well-being of more people in more places and to begin to truly change the narrative around how we design and operate the spaces where we spend our time.
“So much of WELL’s success is due to our WELL APs and WELL Faculty, an active and growing community that brings education about WELL to colleagues and clients around the world,” he continued. “Together with the market reach of our 130+ organizational members, this combined leadership has played a critical role in IWBI’s journey towards market transformation, one that puts the people we care about squarely in the center of every decision we make.”
Over the course of 2019, nearly four times as many new projects registered to pursue WELL as throughout all of 2018.
“Halfway to a billion is one thing, but what’s truly remarkable is the pace of adoption,” said Rachel Gutter, President of IWBI. “WELL entered the market in 2014, and it took roughly four years to reach 250 million square feet, but it’s only taken a year to double that to a half-billion. While that’s a potent market signal, it really reflects an unbelievable rise of a dedicated community around the world that is committed to investing in health.”
To build upon this growth and momentum, IWBI also has leveraged new partnership opportunities to reach priority markets and scale the benefits of delivering better buildings.
“We are fostering a global movement to radically transform how we deliver on the promise of better buildings that help all people thrive,” said Gutter. “We know we can’t do it alone. That’s why last year we announced a partnership with Enterprise Community Partners to bridge sustainability and health by integrating WELL with the Enterprise 2020 Green Communities Criteria, which is the leading building standard for green affordable housing construction nationwide.” Currently 27 states and Washington D.C. require or incentivize Enterprise Green Communities certification for affordable housing developments that receive public funds. Beginning in October projects meeting these requirements will also be certified to WELL.
“As we continue to scale across every dimension, it becomes more important than ever that we find a place and time for our community to experience the power of this movement,” said Fedrizzi. “That’s why in two short months, we’ll convene in Scottsdale, Arizona, for the launch of The WELL Conference , a gathering designed to inspire, energize and celebrate the people and organizations who are helping us change the world.”
In collaboration with the American Society of Interior Designers (ASID) and Emerald Expositions (Emerald), The WELL Conference will bring together architectural, design and engineering communities, along with real estate developers, corporate officials, public health practitioners, and technology companies. Centered on the idea that our buildings and communities are fundamental to our health and well-being, the event will unite a diverse representation of industries and sectors around a shared mission.
“Given these enormous accomplishments in just the five years since WELL first launched, we’re beyond excited to see what this new decade will bring,” said Fedrizzi. “Every new project, WELL AP, WELL Faculty and IWBI member helps us take more steps forward in this journey. And when the mission is to improve the health of people, every milestone is worth celebrating.”
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. WELL v2 is the latest version of its popular WELL Building Standard, and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here .
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005834/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
